An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease

Inclusion Criteria: * Availability of written informed consent obtained from the patient before the start of any procedures related to the study. * Male and female patients aged 18-75 years, inclusive, at the time of signing the informed consent form. * Patients with a documented diagnosis of adult Still's disease in accordance with the classification criteria of Yamaguchi M. et al. (J. Rheumatology, 1992) and the duration of the disease is at least 2 months before signing the Informed Consent Form. * Disease activity ≥2.6 according to DAS28-ESR. * No change in the dosing regimen of methotrexate (maximum 20 mg/m2/week) or other immunosuppressive agent for at least 6 weeks before randomization and/or no change in the dosing regimen of one nonsteroidal anti-inflammatory drug (NSAID) as treatment for adult Still's disease for at least 14 days before randomization and/or no change in the dosage regimen of the glucocorticosteroid drug for at least 7 days before randomization. * Negative result of intradermal test with tuberculosis allergen / IGRA test at screening or within 6 months before screening. Patients with missing screening data can only be included in the study if they undergo immunodiagnosis of tuberculosis infection and the result is negative. * Agreement to adhere to adequate methods of contraception throughout the study and for 3 months after the end of canakinumab therapy. Exclusion Criteria: * Diagnosis of macrophage activation syndrome (MAS) within the last 3 mo…